Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.

Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC.

Leuk Lymphoma. 2019 Jan 17:1-7. doi: 10.1080/10428194.2018.1548705. [Epub ahead of print]

PMID:
30652523
2.

Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?

Jain T, Kunze KL, Khetarpal BK, McCallen MR, Betcher JA, Ofori HT, Khera N, Slack JL, Leis JF, Sproat LZ, Noel P, Palmer J.

Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1562183. [Epub ahead of print]

PMID:
30626239
3.

Learning Style Preferences of Practicing Nurses.

Mangold K, Kunze KL, Quinonez MM, Taylor LM, Tenison AJ.

J Nurses Prof Dev. 2018 Jul/Aug;34(4):212-218. doi: 10.1097/NND.0000000000000462.

PMID:
29975315
4.

Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.

Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J.

Bone Marrow Transplant. 2019 Feb;54(2):204-211. doi: 10.1038/s41409-018-0226-1. Epub 2018 May 24.

PMID:
29795431
5.

Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.

Rock BM, Hengel SM, Rock DA, Wienkers LC, Kunze KL.

Mol Pharmacol. 2014 Dec;86(6):665-74. doi: 10.1124/mol.114.094862. Epub 2014 Oct 1.

PMID:
25274602
6.

Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.

Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N.

Clin Pharmacol Ther. 2014 Jun;95(6):653-62. doi: 10.1038/clpt.2014.50. Epub 2014 Feb 25.

7.

Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Zhang N, Seguin RP, Kunze KL, Zhang YY, Jeong H.

Drug Metab Dispos. 2013 Dec;41(12):2114-23. doi: 10.1124/dmd.113.053330. Epub 2013 Sep 17.

8.

Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.

Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N.

Drug Metab Dispos. 2013 Dec;41(12):2056-65. doi: 10.1124/dmd.113.052639. Epub 2013 Jun 19.

9.

Risk assessment of mechanism-based inactivation in drug-drug interactions.

Fujioka Y, Kunze KL, Isoherranen N.

Drug Metab Dispos. 2012 Sep;40(9):1653-7. doi: 10.1124/dmd.112.046649. Epub 2012 Jun 8.

10.

Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.

Peng CC, Shi W, Lutz JD, Kunze KL, Liu JO, Nelson WL, Isoherranen N.

Drug Metab Dispos. 2012 Mar;40(3):426-35. doi: 10.1124/dmd.111.042739. Epub 2011 Nov 21.

11.

Allosteric activation of cytochrome P450 3A4 by α-naphthoflavone: branch point regulation revealed by isotope dilution analysis.

Woods CM, Fernandez C, Kunze KL, Atkins WM.

Biochemistry. 2011 Nov 22;50(46):10041-51. doi: 10.1021/bi2013454. Epub 2011 Oct 28.

12.

Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.

Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N.

Clin Pharmacol Ther. 2011 Jun;89(6):888-95. doi: 10.1038/clpt.2011.53. Epub 2011 Apr 13.

13.

Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.

Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N.

Clin Pharmacol Ther. 2010 Oct;88(4):499-505. doi: 10.1038/clpt.2010.119. Epub 2010 Aug 25.

14.

Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.

Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL.

Drug Metab Dispos. 2010 Jun;38(6):963-72. doi: 10.1124/dmd.110.032391. Epub 2010 Mar 3.

15.

Mechanism of formation of the ester linkage between heme and Glu310 of CYP4B1: 18O protein labeling studies.

Baer BR, Kunze KL, Rettie AE.

Biochemistry. 2007 Oct 16;46(41):11598-605. Epub 2007 Sep 19.

16.

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N.

Clin Pharmacol Ther. 2008 Jan;83(1):77-85. Epub 2007 May 9.

17.

Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.

Zhao P, Lee CA, Kunze KL.

Drug Metab Dispos. 2007 May;35(5):704-12. Epub 2007 Feb 9.

PMID:
17293381
18.

Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.

Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, Atkins WM.

Biochemistry. 2006 May 23;45(20):6341-53.

19.

Stereochemical aspects of itraconazole metabolism in vitro and in vivo.

Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N.

Drug Metab Dispos. 2006 Apr;34(4):583-90. Epub 2006 Jan 13. Erratum in: Drug Metab Dispos. 2012 Dec;40(12):2381.

PMID:
16415110
20.

Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study.

Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, Campbell AP, Kunze KL, Nelson SD.

Biochemistry. 2005 Nov 1;44(43):14143-51.

PMID:
16245930
21.

Sites of covalent attachment of CYP4 enzymes to heme: evidence for microheterogeneity of P450 heme orientation.

Baer BR, Schuman JT, Campbell AP, Cheesman MJ, Nakano M, Moguilevsky N, Kunze KL, Rettie AE.

Biochemistry. 2005 Oct 25;44(42):13914-20.

PMID:
16229480
22.

Oxidation of caffeine by CYP1A2: isotope effects and metabolic switching.

Regal KA, Kunze KL, Peter RM, Nelson SD.

Drug Metab Dispos. 2005 Dec;33(12):1837-44. Epub 2005 Aug 31.

PMID:
16135658
23.

Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes.

Zhao P, Kunze KL, Lee CA.

Drug Metab Dispos. 2005 Jun;33(6):853-61. Epub 2005 Mar 2.

PMID:
15743977
24.

Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.

McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE.

Drug Metab Dispos. 2004 Oct;32(10):1083-91.

PMID:
15377640
25.

Role of itraconazole metabolites in CYP3A4 inhibition.

Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE.

Drug Metab Dispos. 2004 Oct;32(10):1121-31. Epub 2004 Jul 8.

PMID:
15242978
26.

Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.

Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF.

Drug Metab Dispos. 2003 Aug;31(8):1043-8.

PMID:
12867493
27.

Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH.

Drug Metab Dispos. 2003 May;31(5):565-71.

PMID:
12695344
28.

Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediate.

Zheng YM, Baer BR, Kneller MB, Henne KR, Kunze KL, Rettie AE.

Biochemistry. 2003 Apr 22;42(15):4601-6.

PMID:
12693958
29.

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.

Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M.

Epilepsia. 2002 Jul;43(7):691-6. Erratum in: Epilepsia 2002 Oct;43(10):1273.

30.

Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.

Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH.

Clin Pharmacol Ther. 2001 Nov;70(5):415-24.

PMID:
11719727
31.

Covalent linkage of prosthetic heme to CYP4 family P450 enzymes.

Henne KR, Kunze KL, Zheng YM, Christmas P, Soberman RJ, Rettie AE.

Biochemistry. 2001 Oct 30;40(43):12925-31.

PMID:
11669629
32.

Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.

Shen DD, Kunze KL, Thummel KE.

Adv Drug Deliv Rev. 1997 Sep 15;27(2-3):99-127.

PMID:
10837554
33.

Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.

Gibbs MA, Baillie MT, Shen DD, Kunze KL, Thummel KE.

Pharm Res. 2000 Mar;17(3):299-305.

PMID:
10801218
34.

Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.

Gibbs MA, Kunze KL, Howald WN, Thummel KE.

Drug Metab Dispos. 1999 May;27(5):596-9.

PMID:
10220488
35.

Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding.

Fisher JM, Wrighton SA, Calamia JC, Shen DD, Kunze KL, Thummel KE.

J Pharmacol Exp Ther. 1999 May;289(2):1143-50.

PMID:
10215698
36.

First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.

Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, Thummel KE.

J Pharmacol Exp Ther. 1999 May;289(2):1134-42.

PMID:
10215697
37.
38.

Subnanomolar quantification of caffeine's in vitro metabolites by stable isotope dilution gas chromatography-mass spectrometry.

Regal KA, Howald WN, Peter RM, Gartner CA, Kunze KL, Nelson SD.

J Chromatogr B Biomed Sci Appl. 1998 Apr 24;708(1-2):75-85.

PMID:
9653949
40.

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE.

J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62.

PMID:
9400033
41.

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.

Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH.

Clin Pharmacol Ther. 1997 Nov;62(5):490-504.

PMID:
9390105
42.

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.

Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K.

Anesthesiology. 1997 Jul;87(1):36-50.

PMID:
9232132
43.

The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.

Gallagher EP, Kunze KL, Stapleton PL, Eaton DL.

Toxicol Appl Pharmacol. 1996 Dec;141(2):595-606.

PMID:
8975785
44.

Relation between plasma and saliva concentrations of enoxacin, ciprofloxacin, and theophylline.

Zhai S, Wei X, Parker BM, Kunze KL, Vestal RE.

Ther Drug Monit. 1996 Dec;18(6):666-71.

PMID:
8946663
45.

Binding of the aflatoxin-glutathione conjugate to mouse glutathione S-transferase A3-3 is saturated at only one ligand per dimer.

McHugh TE, Atkins WM, Racha JK, Kunze KL, Eaton DL.

J Biol Chem. 1996 Nov 1;271(44):27470-4.

46.

First-pass metabolism of midazolam by the human intestine.

Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE.

Clin Pharmacol Ther. 1996 Jul;60(1):14-24.

PMID:
8689807
47.

Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.

Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF.

Drug Metab Dispos. 1996 May;24(5):610-4.

PMID:
8723744
48.

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR.

Clin Pharmacol Ther. 1996 May;59(5):491-502.

PMID:
8646820
49.
50.

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF.

Drug Metab Dispos. 1996 Apr;24(4):422-8.

PMID:
8801057

Supplemental Content

Loading ...
Support Center